Dimitrios Nasioudis, Stefan Gysler, Nawar A Latif, Robert L Giuntoli, Sarah H Kim, Emily M Ko
{"title":"早期子宫内膜样卵巢癌患者淋巴结转移的发生率。","authors":"Dimitrios Nasioudis, Stefan Gysler, Nawar A Latif, Robert L Giuntoli, Sarah H Kim, Emily M Ko","doi":"10.1016/j.ijgc.2025.101897","DOIUrl":null,"url":null,"abstract":"<p><p>The incidence of lymph node metastases for apparent early-stage endometrioid ovarian carcinoma is not well-known. We accessed the National Cancer Database and selected patients with apparent stage I endometrioid ovarian carcinoma undergoing surgery between 2004 and 2015. The rate of lymphadenectomy was 76.9%, with a median of 12.5 lymph nodes removed. The overall incidence of lymph node metastasis was 2.2%, specifically, 1.2% for grade 1, 2.2% for grade 2, and 5.1% for grade 3 tumors (p < .001). After controlling for disease sub-stage, patients with grade 2 tumors were nearly twice (OR 1.78, 95% CI 1.20 to 2.63), and patients with grade 3 tumors were nearly 4 times (OR 4.1, 95% CI 2.74 to 6.22) as likely as those with grade 1 tumor to have lymph node metastases. Surgical staging identifies a very low rate of lymph node metastases for patients with apparent early-stage grade 1 endometrioid ovarian carcinoma, suggesting that lymphadenectomy can be omitted for these patients.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101897"},"PeriodicalIF":4.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence of lymph node metastases in patients with apparent early-stage endometrioid ovarian carcinoma.\",\"authors\":\"Dimitrios Nasioudis, Stefan Gysler, Nawar A Latif, Robert L Giuntoli, Sarah H Kim, Emily M Ko\",\"doi\":\"10.1016/j.ijgc.2025.101897\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The incidence of lymph node metastases for apparent early-stage endometrioid ovarian carcinoma is not well-known. We accessed the National Cancer Database and selected patients with apparent stage I endometrioid ovarian carcinoma undergoing surgery between 2004 and 2015. The rate of lymphadenectomy was 76.9%, with a median of 12.5 lymph nodes removed. The overall incidence of lymph node metastasis was 2.2%, specifically, 1.2% for grade 1, 2.2% for grade 2, and 5.1% for grade 3 tumors (p < .001). After controlling for disease sub-stage, patients with grade 2 tumors were nearly twice (OR 1.78, 95% CI 1.20 to 2.63), and patients with grade 3 tumors were nearly 4 times (OR 4.1, 95% CI 2.74 to 6.22) as likely as those with grade 1 tumor to have lymph node metastases. Surgical staging identifies a very low rate of lymph node metastases for patients with apparent early-stage grade 1 endometrioid ovarian carcinoma, suggesting that lymphadenectomy can be omitted for these patients.</p>\",\"PeriodicalId\":14097,\"journal\":{\"name\":\"International Journal of Gynecological Cancer\",\"volume\":\"35 6\",\"pages\":\"101897\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecological Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijgc.2025.101897\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2025.101897","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
早期子宫内膜样卵巢癌的淋巴结转移发生率尚不清楚。我们访问了国家癌症数据库,并选择了2004年至2015年间接受手术的I期子宫内膜样卵巢癌患者。淋巴结切除术率为76.9%,平均切除12.5个淋巴结。淋巴结转移的总发生率为2.2%,其中1级肿瘤为1.2%,2级肿瘤为2.2%,3级肿瘤为5.1% (p < 0.001)。在控制疾病分期后,2级肿瘤患者发生淋巴结转移的可能性几乎是1级肿瘤患者的2倍(OR 1.78, 95% CI 1.20至2.63),3级肿瘤患者发生淋巴结转移的可能性几乎是1级肿瘤患者的4倍(OR 4.1, 95% CI 2.74至6.22)。手术分期表明,明显的早期1级子宫内膜样卵巢癌患者的淋巴结转移率非常低,提示对这些患者可以省略淋巴结切除术。
Incidence of lymph node metastases in patients with apparent early-stage endometrioid ovarian carcinoma.
The incidence of lymph node metastases for apparent early-stage endometrioid ovarian carcinoma is not well-known. We accessed the National Cancer Database and selected patients with apparent stage I endometrioid ovarian carcinoma undergoing surgery between 2004 and 2015. The rate of lymphadenectomy was 76.9%, with a median of 12.5 lymph nodes removed. The overall incidence of lymph node metastasis was 2.2%, specifically, 1.2% for grade 1, 2.2% for grade 2, and 5.1% for grade 3 tumors (p < .001). After controlling for disease sub-stage, patients with grade 2 tumors were nearly twice (OR 1.78, 95% CI 1.20 to 2.63), and patients with grade 3 tumors were nearly 4 times (OR 4.1, 95% CI 2.74 to 6.22) as likely as those with grade 1 tumor to have lymph node metastases. Surgical staging identifies a very low rate of lymph node metastases for patients with apparent early-stage grade 1 endometrioid ovarian carcinoma, suggesting that lymphadenectomy can be omitted for these patients.
期刊介绍:
The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.